Atara Biotherapeutics, Inc. financial data

Symbol
ATRA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1280 Rancho Conejo Blvd, Thousand Oaks, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 52.6 % -69%
Quick Ratio 9.6 % +18.4%
Debt-to-equity -235 % +81.4%
Return On Equity 86.1 % -94%
Return On Assets -63.9 % +47.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.86M shares -95.1%
Common Stock, Shares, Outstanding 5.86M shares +37.6%
Entity Public Float 41M USD -74.6%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 7.49M shares +76.8%
Weighted Average Number of Shares Outstanding, Diluted 7.49M shares +76.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 151M USD -32.6%
General and Administrative Expense 39.9M USD -21.7%
Costs and Expenses 212M USD -25.4%
Operating Income (Loss) -83.4M USD +69.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -85.4M USD +69.1%
Income Tax Expense (Benefit) -12K USD -180%
Net Income (Loss) Attributable to Parent -85.4M USD +69.1%
Earnings Per Share, Basic -11.4 USD/shares +82.5%
Earnings Per Share, Diluted -11.4 USD/shares +82.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25M USD -3.14%
Accounts Receivable, after Allowance for Credit Loss, Current 1.48M USD -95.7%
Inventory, Net 10.7M USD +9.78%
Other Assets, Current 10.1M USD +63.6%
Assets, Current 64.9M USD -36.3%
Property, Plant and Equipment, Net 1.29M USD -66.4%
Operating Lease, Right-of-Use Asset 39.8M USD -27.5%
Other Assets, Noncurrent 3.1M USD -35.9%
Assets 109M USD -34.1%
Accounts Payable, Current 4.37M USD +18.5%
Employee-related Liabilities, Current 6.59M USD -42.8%
Accrued Liabilities, Current 6.03M USD -68.3%
Contract with Customer, Liability, Current 77.8M USD
Liabilities, Current 135M USD -5.38%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 29.9M USD -34.5%
Other Liabilities, Noncurrent 3.27M USD -29.4%
Liabilities 206M USD -22%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8K USD
Retained Earnings (Accumulated Deficit) -2.05B USD -4.34%
Stockholders' Equity Attributable to Parent -97.3M USD +1.96%
Liabilities and Equity 109M USD -34.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.6M USD +22.9%
Net Cash Provided by (Used in) Financing Activities 24.1M USD +10173%
Net Cash Provided by (Used in) Investing Activities 14.7M USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 5.86M shares +37.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.2M USD -3.12%
Interest Paid, Excluding Capitalized Interest, Operating Activities 114K USD +1.79%
Deferred Tax Assets, Valuation Allowance 368M USD -22.4%
Deferred Tax Assets, Gross 377M USD -22.5%
Operating Lease, Liability 42.8M USD -24.9%
Depreciation 2.7M USD -27%
Payments to Acquire Property, Plant, and Equipment 127K USD -68.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -85.2M USD +68.9%
Lessee, Operating Lease, Liability, to be Paid 54M USD -27.6%
Property, Plant and Equipment, Gross 18.6M USD -5.7%
Operating Lease, Liability, Current 12.9M USD +14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 15.7M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 17M USD -1.19%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11.2M USD -36.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.49M USD -68.2%
Deferred Tax Assets, Operating Loss Carryforwards 259M USD -19.8%
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 37.9M USD -76.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.32M USD -42.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 8.75M USD -24.6%
Share-based Payment Arrangement, Expense 27M USD -40.5%
Interest Expense 4.62M USD -12.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%